Netrin1‐Enriched Exosomes From Genetically Modified ADSCs as a Novel Treatment for Diabetic Limb Ischemia
Yihong Jiang,Jiateng Hu,Chaoyi Cui,Zhaoxi Peng,Sen Yang,Jiahao Lei,Bo Li,Xinrui Yang,Jinbao Qin,Minyi Yin,Xiaobing Liu,Kaichuang Ye,Zhijue Xu,Xing Zhang,Xinwu Lu
DOI: https://doi.org/10.1002/adhm.202403521
IF: 10
2024-10-25
Advanced Healthcare Materials
Abstract:This study identifies Netrin1 as a novel biomarker and therapeutic target for diabetic limb ischemia (DLI), with engineered Netrin1‐enriched exosomes (N‐Exos) showing superior efficacy in promoting angiogenesis, reducing apoptosis, and regulating inflammation. Through in vitro and in vivo validation, N‐Exos demonstrate significant therapeutic potential. The findings offer mechanistic insights and a promising non‐cell‐based alternative for DLI treatment. Diabetic limb ischemia (DLI) is a frequent complication of diabetes and the leading cause of non‐traumatic amputation. Traditional treatments like stent placement and bypass surgery may not suit all patients. Exosome transplantation has emerged as a promising therapy. Netrin1, a protective cardiovascular factor, has an unclear role in DLI. This study investigates the role of Netrin1 in DLI patients and evaluates the therapeutic potential of exosomes derived from Netrin1‐overexpressing adipose‐derived stem cells (N‐ADSCs). The expression of Netrin1 is significantly decreased in both endothelial cells and serum of DLI patients, highlighting its potential as a biomarker or therapeutic target. In vitro, Netrin1‐enriched exosomes (N‐Exos) promoted human umbilical vein endothelial cell (HUVEC) proliferation, migration, tube formation, and increased resistance to apoptosis under high glucose conditions. These protective effects are mediated through PI3K/AKT/eNOS and MEK/ERK pathways, and N‐Exos further facilitated macrophage polarization from M1 to M2. In vivo, N‐Exos demonstrates superior therapeutic effects over ADSC exosomes (Exos), including enhanced angiogenesis, improved collateral artery remodeling, reduced inflammation, and muscle protection. Collectively, these findings identify Netrin1 as a critical factor in DLI and underscore its significance in disease progression and therapeutic strategies. N‐Exos offers a promising non‐cellular therapeutic approach for the treatment of DLI.
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials